membranous nephropathy

News

A study of Roche's Gazyva has raised the prospect of a first approved therapy for the rare kidney disorder primary membranous nephropathy.

News

Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.